Results 1 to 10 of about 16,238 (237)

Canakinumab as treatment for COVID-19-related pneumonia: A prospective case-control study

International Journal of Infectious Diseases, 2021
Objectives: Canakinumab is an IL-1β antibody that neutralises the activity of IL-1β. This study examined the efficacy and safety of canakinumab in patients with moderate COVID-19-related pneumonia.
DANIELE GENERALI, Luca Pianta, Valeria De Giuli   +2 more
exaly   +3 more sources

Long-term safety of canakinumab in patients with systemic juvenile idiopathic arthritis: 5-year results from the Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry [PDF]

Pediatric Rheumatology Online Journal
Background Systemic juvenile idiopathic arthritis (SJIA) is a severe form of juvenile idiopathic arthritis characterized by fever, rash, chronic arthritis, and systemic inflammation.
Colleen Correll, Alis Burciu, Amita Bansal, Anne Dennos, Deepak Narayanswamy, Elodie Aubrun, Laura E. Schanberg, Li Yuhan, Rahel Schneider, Stephen Balevic, Yukiko Kimura, Timothy Beukelman, for the CARRA Registry investigators   +12 more
doaj   +2 more sources

CANOPY-N: A Phase 2 Study of Canakinumab or Pembrolizumab, Alone or in Combination, as Neoadjuvant Therapy in Patients With Resectable, Stage IB–IIIA NSCLC [PDF]

JTO Clinical and Research Reports
Introduction: Canakinumab is a human monoclonal anti–interleukin-1β antibody with the potential to enhance the activity of programmed death-ligand 1 inhibitors by inhibiting protumor inflammation.
Jay M. Lee, MD, Jean-Louis Pujol, MD, PhD, Jun Zhang, MD, PhD, Oleg Leonov, MD, PhD, Masahiro Tsuboi, MD, PhD, Edward S. Kim, MD, MBA, Calvin Ng, MD, Nicolas Moreno-Mata, MD, PhD, Amy Cummings, MD, PhD, Ilhan Hacibekiroglu, MD, Abidin Sehitogullari, MD, Nirmal Veeramachaneni, MD, Cathy Spillane, PhD, Jiawei Duan, PhD, Claudia Bossen, PhD, Alexander Savchenko, MD, PhD, Chiara Lobetti-Bodoni, MD, PhD, Tony Mok, MD, Pilar Garrido, MD   +18 more
doaj   +2 more sources

Safety and efficacy of canakinumab treatment for undifferentiated autoinflammatory diseases: the data of a retrospective cohort two-centered study [PDF]

Frontiers in Medicine, 2023
IntroductionThe blockade of interleukine-1 (anakinra and canakinumab) is a well-known highly effective tool for monogenic autoinflammatory diseases (AIDs), such as familial Mediterranean fever, tumor necrosis factor receptor-associated periodic syndrome,
Ekaterina Alexeeva, Ekaterina Alexeeva, Meiri Shingarova, Meiri Shingarova, Tatyana Dvoryakovskaya, Tatyana Dvoryakovskaya, Olga Lomakina, Anna Fetisova, Ksenia Isaeva, Aleksandra Chomakhidze, Kristina Chibisova, Elizaveta Krekhova, Aleksandra Kozodaeva, Kirill Savostyanov, Aleksandr Pushkov, Ilya Zhanin, Dmitry Demyanov, Evgeny Suspitsin, Evgeny Suspitsin, Konstantin Belozerov, Mikhail Kostik   +20 more
doaj   +2 more sources

Effectiveness of Canakinumab for First‐Line Steroid‐Free Treatment in Systemic‐Onset Juvenile Idiopathic Arthritis and Juvenile Still Disease [PDF]

ACR Open Rheumatology
Objective This prospective study assesses the response to canakinumab monotherapy administered as three monthly subcutaneous injections in glucocorticoid‐naïve patients with newly diagnosed systemic juvenile idiopathic arthritis (sJIA) and Still disease ...
Gerd Horneff, Tilman Kallinich, Markus Hufnagel, Kirsten Minden, Frank Weller‐Heinemann, Ralf Trauzeddel, Dirk Foell, Claas Hinze, Fabienne Staubi, Ariane Klein   +9 more
doaj   +2 more sources

Canakinumab in patients with COVID-19 and type 2 diabetes – A multicentre, randomised, double-blind, placebo-controlled trial

EClinicalMedicine, 2022
Summary: Background: Patients with type 2 diabetes and obesity have chronic activation of the innate immune system possibly contributing to the higher risk of hyperinflammatory response to SARS-CoV2 and severe COVID-19 observed in this population.
Matthias Hepprich, Jonathan M. Mudry, Claudia Gregoriano, Francois R. Jornayvaz, Sebastian Carballo, Anne Wojtusciszyn, Pierre-Alexandre Bart, Jean-Daniel Chiche, Stefan Fischli, Thomas Baumgartner, Claudia Cavelti-Weder, Dominique L. Braun, Huldrych F. Günthard, Felix Beuschlein, Anna Conen, Emily West, Egon Isenring, Stefan Zechmann, Gabriela Bucklar, Yoann Aubry, Ludovic Dey, Beat Müller, Patrick Hunziker, Philipp Schütz, Marco Cattaneo, Marc Y. Donath   +25 more
doaj   +2 more sources

Long-term Effectiveness and Safety of Canakinumab in Patients with TRAPS: Analysis of the RELIANCE Non-Interventional Study [PDF]

Rheumatology and Therapy
Introduction This is an interim analysis of the long-term effectiveness and safety of canakinumab in the tumor necrosis factor receptor-associated periodic syndrome (TRAPS) cohort of the RELIANCE non-interventional study.
Norbert Blank, Catharina Schuetz, Markus Hufnagel, Gerd Horneff, Michael Borte, Tilmann Kallinich, Prasad T. Oommen, Ales Janda, Joerg Henes, Julia Weber-Arden, Michael Stock, Jasmin B. Kuemmerle-Deschner   +11 more
doaj   +2 more sources

Canakinumab treatment patterns in sJIA, FMF, TRAPS, and MKD/HIDS: real-world insights from a Belgian non-interventional study [PDF]

BMC Rheumatology
Background Canakinumab, an IL-1β inhibitor, has demonstrated long-term efficacy and safety in patients with sJIA, FMF, TRAPS, and MKD/HIDS who experience inadequate disease control with conventional treatments. This non-interventional study aimed to gain
Michel Moutschen, Cécile Boulanger, Joke Dehoorne, Rik Joos, Florence Roufosse, Vito Sabato, Jeroen van der Hilst, Eleonore Maury, Hilde Rabijns, Marijn Witterzeel, Carine Wouters   +10 more
doaj   +2 more sources

Neonatal-onset multisystem inflammatory disease caused by a de novo NLRP3 gene mutation: a case report and literature review [PDF]

Frontiers in Pediatrics
BackgroundNeonatal-onset multisystem inflammatory disease (NOMID) is a rare autoinflammatory disease caused by NLRP3 mutations, leading to excessive interleukin-1β activation and potential irreversible organ damage.Case descriptionWe report a female ...
Lingxia Zhao, Lingkong Zeng, Wenhao Yuan
doaj   +2 more sources

Long-term safety and effectiveness of canakinumab in patients with monogenic autoinflammatory diseases: results from the interim analysis of the RELIANCE registry [PDF]

RMD Open
Objective Interim analysis of the RELIANCE registry, an on-going, non-interventional, open-label, multicentre, prospective study evaluating the long-term safety, dosing regimens and effectiveness of canakinumab in patients with cryopyrin-associated ...
Tilmann Kallinich, Juergen Rech, Ivan Foeldvari, Norbert Blank, Frank Weller-Heinemann, Gerd Horneff, Ioana Andreica, Joerg Henes, Jasmin B Kuemmerle-Deschner, Florian Meier, Frank Dressler, Michael Borte, Markus Hufnagel, Birgit Kortus-Götze, Prasad T Oommen, Tobias Krickau, Aleš Janda, Catharina Schuetz, Michael Fiene, Julia Weber-Arden   +19 more
doaj   +2 more sources